WO2025120534 - COMPOSITIONS OF XCL EXPRESSING CELLS AND METHODS OF USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/120534
Publication Date
12.06.2025
International Application No.
PCT/IB2024/062204
International Filing Date
04.12.2024
Title **
[English]
COMPOSITIONS OF XCL EXPRESSING CELLS AND METHODS OF USE THEREOF
[French]
COMPOSITIONS DE CELLULES EXPRIMANT XCL ET PROCÉDÉS D'UTILISATION ASSOCIÉS
Applicants **
KING'S COLLEGE LONDON
Inventors
DAVIES, Daniel
KAMDAR, Shraddha
HAYDAY, Adrian
Priority Data
63/606,047
04.12.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2663 | |
| EPO | Filing, Examination, Granting | 17393 | |
| Japan | Filing, Examination, Granting | 2688 | |
| South Korea | Filing, Examination, Granting | 3111 | |
| USA | Filing, Examination, Granting | 8340 |
Total:
34,195
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein is an engineered immune cell expressing XCL1(X-C motif chemokine ligand 1) or a functional variant thereof, wherein the immune cell is a gamma delta (γδ) T cell. Also provided are methods of modulating immune function by administering said immune cell, and methods of treating cancer and other immune diseases.[French]
L'invention concerne une cellule immunitaire modifiée exprimant XCL1 (ligand 1 de chimiokine à motif X-C) ou un variant fonctionnel de celle-ci, la cellule immunitaire étant un lymphocyte T gamma delta (γδ). L'invention concerne également des procédés de modulation de la fonction immunitaire par administration de ladite cellule immunitaire, ainsi que des méthodes de traitement du cancer et d'autres maladies immunitaires.